Tramadol/Diclofenac Fixed‐Dose Combination for Acute Pain Management: Bioavailability Assessment of a Generic Product
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1410 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Thalita Martins da Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Unit, Adium S.A., São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Tramadol, Diclofenac, Cross-Over Studies, Therapeutic Equivalency. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
The multimodal analgesia strategy for acute pain involves using 2 or more analgesic medications with distinct mechanisms of action. This study assessed the bioavailability and tolerability of 2 tramadol hydrochloride (50 mg)/diclofenac sodium (50 mg) fixed‐dose combination formulations under fed conditions to attend the Brazilian regulatory requirements for generic product registration. An open‐label, randomized, single‐dose, 2‐period, 2‐way crossover trial was conducted, including healthy subjects of both sexes. Subjects received a single dose of either the test or reference formulation of tramadol/diclofenac fixed‐dose combination tablets with a 7‐day washout period. Blood samples were collected up to 36 hours after dosing for tramadol and 12 hours for diclofenac and quantified using a validated liquid chromatography‐tandem mass spectrometry method. Of 56 subjects enrolled, 53 completed the study. The 90% confidence intervals for maximum plasma concentration and area under the concentration‐time curve from time 0 to the last quantifiable concentration were within acceptable bioequivalence limits of 80%‐125%. Considering the results presented in this study, the test formulation is bioequivalent to the reference formulation and could be interchangeable in medical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Unit, Adium S.A., São Paulo, São Paulo, Brazil.
- Corporate Department of Clinical Studies, Adium S.A. Headquarters, Buenos Aires, Buenos Aires, Argentina.
- Bioequivalence Unit, Centro Avançado de Estudos e Pesquisas Ltd., Campinas, Brazil.
- Medical Department, Adium S.A., São Paulo, São Paulo, Brazil.
Zitieren
APA
da Silva, T. M., Davanço, M. G., Meulman, J., Vianna, D. R. B., Costa, F., Pacheco, F. B. C., Carandina, S. A. C., Issa, E., & Vespasiano, C. F. P. (2024). Tramadol/Diclofenac Fixed‐Dose Combination for Acute Pain Management: Bioavailability Assessment of a Generic Product. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1410
Vancouver
da Silva TM, Davanço MG, Meulman J, Vianna DRB, Costa F, Pacheco FBC, et al. Tramadol/Diclofenac Fixed‐Dose Combination for Acute Pain Management: Bioavailability Assessment of a Generic Product. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1410
BibTeX
@article{daSilva2024,
author = {da Silva, Thalita Martins and Davanço, Marcelo Gomes and Meulman, Jessica and Vianna, Débora Renz Barreto and Costa, Fernando and Pacheco, Fernando Bastos Canton and Carandina, Silvana Aparecida Calafatti and Issa, Eduardo and Vespasiano, Celso Francisco Pimentel},
title = {Tramadol/Diclofenac Fixed‐Dose Combination for Acute Pain Management: Bioavailability Assessment of a Generic Product},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1410}
}
EUVIMED